



IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION

100 Army Post Road, Des Moines, Iowa 50315 (515) 725-1295 • Fax (515) 725-1010

Bruce Alexander, R.Ph., Pharm.D., BCPP
Laura Ann Griffith, D.O.

Craig Logemann, R.Ph., Pharm.D., BCPS
Dan Murphy, R.Ph.
Susan Parker, Pharm.D.

Laurie Pestel, Pharm.D.
Richard Rinehart, M.D.
Sara Schutte-Schenck, D.O., FAAP

Professional Staff: Thomas Kline, D.O.

Shelly Larson, R.Ph.
Director, (515)725-1295

Janalyn Phillips, R.Ph.

The Iowa Medicaid Drug Utilization Review Commission will meet on Wednesday, May 7, 2008 from 9:30 am to 1:30 pm. This meeting will be held at the Iowa Foundation for Medical Care, 6000 Westown Parkway in West Des Moines.

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. This public comment period shall last no more than 15 minutes. Individuals may respectfully offer comments, with priority being given to the current Commission meeting agenda items.

Meeting Agenda – May 7, 2008 – starting at 9:30 am

1. **Welcome and introductions**
2. **Approval of minutes**
3. **Program statistics and evaluations**
 - a. Intervention case studies
 - b. Management reports
4. **ProDUR**
 - a. Mental Health ProDUR consolidation edits
5. **Focus Studies**
 - a. Serotonin 5-HT1-receptor Agonists
 - b. Long term muscle relaxant use
 - c. Underutilization of ACE-I/ARB – Information
 - d. Underutilization of Beta-Blockers Post MI and in patients with CAD – Information
6. **New Trends**
 - a. Concomitant therapy with benzotropine and atypical antipsychotics
7. **OPEN COMMENT – THIS COMMENT PERIOD SHALL LAST NO MORE THAN 15 MINUTES. INDIVIDUALS MAY RESPECTFULLY OFFER COMMENTS, WITH PRIORITY GIVEN TO CURRENT COMMISSION MEETING AGENDA ITEMS. BEFORE SPEAKING, A CONFLICT OF INTEREST DISCLOSURE FORM NEEDS TO BE SIGNED AND GIVEN TO THE IOWA MEDICAID DUR DIRECTOR.**
8. **Prior Authorization**
 - a. Non-Steroidal Anti-inflammatory Drugs
 - b. Biologicals
 - c. Lyrica®
 - d. Modified Formulations (Seroquel® XR, Invega®, and Pristiq™)
 - e. ACE-I and ARBs
9. **OPEN COMMENT – THIS COMMENT PERIOD SHALL LAST NO MORE THAN 15 MINUTES.**
10. **Retrospective Criteria Review**
 - a. Cardiac Drugs, Antiarrhythmic Agents 24:04.00
 - b. Cardiac Drugs, Beta-Blockers 24:04.00
11. **Miscellaneous**
 - a. Recommendation Letter
 - b. DUR Digest
 - c. MedWatch
 - d. Smoking Cessation
12. **Articles of Interest**
13. **Adjournment**